###begin article-title 0
###xml 30 35 <span type="species:ncbi:4932">yeast</span>
Intramolecular interaction of yeast TFIIB in transcription control
###end article-title 0
###begin p 1
To whom correspondence should be addressed. Tel: +1 513 636 7977; Fax: +1 513 636 4317; Email: jun.ma@chmcc.org
###end p 1
###begin p 2
###xml 361 368 361 368 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 442 450 442 450 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 710 718 710 718 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 723 730 723 730 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 162 167 <span type="species:ncbi:4932">yeast</span>
###xml 280 285 <span type="species:ncbi:9606">human</span>
###xml 961 966 <span type="species:ncbi:4932">yeast</span>
The general transcription factor TFIIB is a key component in the eukaryotic RNA polymerase II (RNAPII) transcriptional machinery. We have previously shown that a yeast TFIIB mutant (called YR1m4) with four amino acid residues in a species-specific region changed to corresponding human residues affects the expression of genes activated by different activators in vivo. We report here that YR1m4 can interact with several affected activators in vitro. In addition, YR1m4 and other mutants with amino acid alterations within the same region can interact with TATA-binding protein (TBP) and RNAPII normally. However, YR1m4 is defective in supporting activator-independent transcription in assays con-ducted both in vitro and in vivo. We further demonstrate that the interaction between the C-terminal core domain and the N-terminal region is weakened in YR1m4 and other related TFIIB mutants. These results suggest that the intramolecular interaction property of yeast TFIIB plays an important role in transcription regulation in cells.
###end p 2
###begin title 3
INTRODUCTION
###end title 3
###begin p 4
###xml 322 323 322 323 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd310c1">1</xref>
###xml 324 325 324 325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd310c4">4</xref>
###xml 376 377 376 377 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd310c5">5</xref>
###xml 527 528 527 528 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd310c6">6</xref>
###xml 721 722 721 722 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd310c7">7</xref>
###xml 926 927 926 927 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd310c8">8</xref>
###xml 928 930 928 930 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd310c12">12</xref>
###xml 1089 1091 1089 1091 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd310c13">13</xref>
###xml 1092 1094 1092 1094 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd310c15">15</xref>
Accurate transcription initiation by RNA polymerase II (RNAPII) requires a group of proteins called general transcription factors (GTFs). Five such GTFs, TATA-binding protein (TBP), TFIIB, TFIIE, TFIIF and TFIIH, enable RNAPII to recognize gene promoters and participate in the assembly of preinitiation complexes (PICs) (1-4). According to a stepwise model of PIC formation (5), TBP binds to DNA first, followed by the binding of TFIIB, then RNAPII-TFIIF and finally TFIIE and TFIIH. TFIIB interacts with both TBP and RNAPII (6) and is believed to provide a physical link between DNA-TBP and RNAPII-TFIIF complexes. A holoenzyme model proposes that TFIIB may be part of a pre-assembled complex called RNAPII holoenzyme (7), which contains several GTFs in addition to RNAPII. Both genetic and biochemical studies have provided strong evidence that TFIIB also participates in the process of transcription start site selection (8-12). In addition, TFIIB interacts with many activators and, therefore, has been proposed to be a target recruited by activators during transcription activation (13-15).
###end p 4
###begin p 5
###xml 102 103 102 103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd310c9">9</xref>
###xml 131 133 131 133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd310c16">16</xref>
###xml 335 336 335 336 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd310c6">6</xref>
###xml 337 339 337 339 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd310c17">17</xref>
###xml 340 342 340 342 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd310c19">19</xref>
###xml 390 392 390 392 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd310c17">17</xref>
###xml 393 395 393 395 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd310c19">19</xref>
###xml 502 504 502 504 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd310c20">20</xref>
###xml 568 570 568 570 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd310c21">21</xref>
###xml 777 779 773 775 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd310c22">22</xref>
###xml 1037 1039 1033 1035 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd310c23">23</xref>
###xml 573 578 <span type="species:ncbi:9606">human</span>
###xml 764 769 <span type="species:ncbi:9606">human</span>
###xml 890 895 <span type="species:ncbi:9606">human</span>
Analysis of TFIIB primary sequences from different eukaryotes has revealed several structural motifs (9), including a zinc ribbon (16) in the N-terminal region and two imperfect repeats in the C-terminal region. The N-terminal region of TFIIB is highly accessible to protease digestion and is critical for the interaction with RNAPII (6,17-19). The C-terminal region is protease resistant (17,19) and hence referred to as the core domain of TFIIB (cTFIIB). According to a solution structure of cTFIIB (20) and a crystal structure of a TATA-TBP-cTFIIB ternary complex (21), human cTFIIB contains two similarly folded domains, each of which consists of five alpha-helices. Biochemical studies have suggested an intramolecular interaction between N- and C-domains of human TFIIB (22), an interaction that could be affected by activators. In addition, recent NMR studies have demonstrated that human cTFIIB itself may adopt multiple conformations, which can be altered by interacting with either the N-terminal domain or the activator VP16 (23). However, there is a relative shortage of evidence that demonstrates the biological importance of the conformational properties of TFIIB (see Discussion).
###end p 5
###begin p 6
###xml 13 37 13 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Saccharomyces cerevisiae</italic>
###xml 120 124 120 124 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SUA7</italic>
###xml 131 132 131 132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd310c9">9</xref>
###xml 246 253 246 253 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 255 257 255 257 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd310c24">24</xref>
###xml 258 260 258 260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd310c25">25</xref>
###xml 396 398 396 398 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd310c24">24</xref>
###xml 481 488 481 488 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 490 492 490 492 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd310c25">25</xref>
###xml 697 704 697 704 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 706 708 706 708 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd310c24">24</xref>
###xml 709 711 709 711 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd310c25">25</xref>
###xml 7 12 <span type="species:ncbi:4932">yeast</span>
###xml 13 37 <span type="species:ncbi:4932">Saccharomyces cerevisiae</span>
###xml 144 149 <span type="species:ncbi:4932">yeast</span>
###xml 183 188 <span type="species:ncbi:9606">human</span>
###xml 234 239 <span type="species:ncbi:9606">human</span>
###xml 285 290 <span type="species:ncbi:4932">yeast</span>
###xml 608 613 <span type="species:ncbi:9606">human</span>
In the yeast Saccharomyces cerevisiae, TFIIB is a monomeric protein of 345 amino acid residues encoded by the essential SUA7 gene (9). Although yeast TFIIB is structurally similar to human TFIIB, it cannot be functionally replaced by human TFIIB in vivo (24,25). Mutational studies of yeast TFIIB revealed a species-specific surface within a solvent-exposed region in the first repeat of cTFIIB (24). Four positions within this region were identified as critical to TFIIB function in vivo (25). A TFIIB mutant, called YR1m4, with amino acid residues changed at these four critical positions to corresponding human TFIIB residues, impaired the expression of genes activated by different activators in vivo (24,25). Thus, the biochemical characterization of this mutant TFIIB will provide important insights into the molecular mechanisms of transcription regulation.
###end p 6
###begin p 7
###xml 390 397 390 397 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 402 410 402 410 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 705 712 705 712 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 773 778 <span type="species:ncbi:4932">yeast</span>
In our efforts to further determine the biochemical properties of YR1m4, we demonstrate that this mutant TFIIB can interact with several activators. We also demonstrate that YR1m4 and other related TFIIB mutants can interact with several individual GTFs, including TBP, TFIIF and RNAPII. We further report that YR1m4 is compromised in supporting activator-independent transcription in both in vivo and in vitro assays. Finally, we demonstrate that an intramolecular interaction between the N- and C-terminal domains of the tested TFIIB mutants is affected, and our experiments reveal a strong correlation between this intramolecular interaction property and activator-independent transcriptional activity in vivo. Our results suggest that the intramolecular interaction of yeast TFIIB plays an important role in transcription regulation.
###end p 7
###begin title 8
MATERIALS AND METHODS
###end title 8
###begin title 9
###xml 0 5 <span type="species:ncbi:4932">Yeast</span>
Yeast strains
###end title 9
###begin p 10
###xml 71 75 71 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTS1</italic>
###xml 101 102 101 102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="gkd310tb1">1</xref>
###xml 108 112 108 112 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SUA7</italic>
###xml 149 152 149 152 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MAT</italic>
###xml 152 153 152 153 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 156 159 156 159 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MAT</italic>
###xml 169 179 165 175 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ace2::HIS3</italic>
###xml 184 251 180 247 <italic xmlns:xlink="http://www.w3.org/1999/xlink">swi5::TRP1 ade2-1 can1-100 his3-11,15 leu2-3,112 lys2 trp1-1 ura3-1</italic>
###xml 275 295 271 291 <italic xmlns:xlink="http://www.w3.org/1999/xlink">sua7::hisG-URA3-hisG</italic>
###xml 447 451 443 447 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LEU2</italic>
###xml 453 455 449 451 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd310c24">24</xref>
###xml 485 489 481 485 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LEU2</italic>
###xml 528 532 524 528 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SUA7</italic>
###xml 572 576 568 572 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SUA7</italic>
###xml 586 590 582 586 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADH1</italic>
###xml 695 699 691 695 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACE2</italic>
###xml 701 705 697 701 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SWI5</italic>
###xml 710 714 706 710 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SUA7</italic>
###xml 4 9 <span type="species:ncbi:4932">yeast</span>
The yeast strains used in the analysis of the expression of endogenous CTS1 gene are listed in Table 1. The SUA7 gene in W303 diploid strain DY5424 (MATa / MATalpha + / ace2::HIS3 + / swi5::TRP1 ade2-1 can1-100 his3-11,15 leu2-3,112 lys2 trp1-1 ura3-1) was disrupted using a sua7::hisG-URA3-hisG disruptor plasmid, and correct disruption was confirmed by Southern blotting. This diploid was transformed with one of two plasmids, pMA1210 or pYR1m4-LEU2 (24). These plasmids, which have LEU2 markers, express either the wild-type SUA7 protein or the YR1m4 mutant version of SUA7 from the ADH1 promoter. The two diploid strains with the plasmids were sporulated and haploid segregants differing at ACE2, SWI5 and SUA7 were isolated.
###end p 10
###begin p 11
###xml 22 25 22 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MAT</italic>
###xml 31 58 27 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink">his3 trp1 ura3-52 leu2 cyh2</italic>
###xml 58 59 54 55 <sup xmlns:xlink="http://www.w3.org/1999/xlink">r</sup>
###xml 58 59 54 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink"><sup>r</sup></italic>
###xml 59 63 55 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LYS2</italic>
###xml 63 64 59 60 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 63 64 59 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink"><sup>+</sup></italic>
###xml 70 74 62 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink">sua7</italic>
###xml 96 100 88 92 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SUA7</italic>
###xml 123 143 115 135 <italic xmlns:xlink="http://www.w3.org/1999/xlink">sua7::hisG-URA3-hisG</italic>
###xml 261 265 253 257 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADH1</italic>
###xml 332 333 324 325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkd310f2">2</xref>
###xml 499 501 491 493 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd310c12">12</xref>
###xml 660 662 652 654 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd310c26">26</xref>
###xml 687 691 679 683 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lacZ</italic>
###xml 724 728 716 720 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HIS3</italic>
###xml 780 784 772 776 <italic xmlns:xlink="http://www.w3.org/1999/xlink">his3</italic>
###xml 4 9 <span type="species:ncbi:4932">yeast</span>
###xml 335 340 <span type="species:ncbi:4932">Yeast</span>
###xml 578 583 <span type="species:ncbi:4932">yeast</span>
The yeast strain 604 (MATalpha his3 trp1 ura3-52 leu2 cyh2rLYS2+ Deltasua7) has its chromosomal SUA7 gene disrupted with a sua7::hisG-URA3-hisG disruptor plasmid, while cell viability is supported by plasmids expressing either wild-type TFIIB or YR1m4 from the ADH1 promoter. This strain was used for reporter gene assays in Figure 2. Yeast strain FP133 used in preparation of TFIIB depleted whole cell extract is a gift of Dr A. Ponticelli. This strain has a temperature-sensitive allele of TFIIB (12), which permits the preparation of a TFIIB-depleted whole cell extract. The yeast strain used in the artificial recruitment assay is a gift of Dr M. Strubin (26). This strain carries a lacZ reporter gene integrated at the HIS3 locus with a single RFX-binding site upstream of a his3 TATA element. The chromosomal TFIIB gene is deleted and a low level of wild-type TFIIB is provided by pYES2 plasmid when cells are grown in glucose medium.
###end p 11
###begin title 12
Plasmid constructions and recombinant protein purification
###end title 12
###begin p 13
###xml 103 104 103 104 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6</sub>
###xml 223 231 223 231 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
DNA fragments were amplified by polymerase chain reactions (PCRs) and cloned into vector pET15b for His6-fusion protein or vector pGEX-KG for glutathione-S-transferase (GST) fusion protein production. DNA fragments used in in vitro transcription and translation were cloned into vector pGEM5 under control of the SP6 promoter. Details of plasmid constructions are available upon request.
###end p 13
###begin p 14
###xml 29 45 29 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Escherichia coli</italic>
###xml 62 63 62 63 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6</sub>
###xml 213 215 203 205 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OD</italic>
###xml 215 220 205 210 <sub xmlns:xlink="http://www.w3.org/1999/xlink">600nm</sub>
###xml 965 966 940 941 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1140 1141 1115 1116 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 1288 1289 1263 1264 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6</sub>
###xml 29 57 <span type="species:ncbi:511693">Escherichia coli strain BL21</span>
Constructs were expressed in Escherichia coli strain BL21 (His6-fusion protein), Xa90 or DH5alpha (GST-fusion proteins). Cells were grown at 37degreesC and IPTG was added to a final concentration of 1 mM when the OD600nm of the culture reached 0.4-0.6. Cells were then incubated at 37degreesC for 3 h and extracts were prepared. For GST-fusion proteins, cell extracts were incubated with glutathione Sepharose-4B beads in buffer B (1x PBS buffer, 1% Triton X-100, 1 mM PMSF, protease inhibitor cocktail tablets added according to the instructions of Boehringer, Indianapolis, IN) at 4degreesC for 1 h. The beads were washed three times with the same buffer with 1 mM PMSF but without other protease inhibitors. The GST-fusion proteins were eluted with buffer E (20 mM reduced glutathione in 50 mM Tris-HCl, pH 8.0). Alternatively, the beads were incubated with 5 U of thrombin in buffer T (50 mM Tris-HCl, pH 8.0, 0.1% beta-mercaptoethanol, 150 mM NaCl, 2.5 mM CaCl2) at room temperature for 2 h to release proteins without GST. Purified proteins were dialyzed against buffer D (20 mM HEPES-KOH, pH 7.5, 20% glycerol, 10 mM EGTA, 10 mM MgSO4, 5 mM DTT). Protein concentrations were determined using a protein assay kit (Bio-Rad, Hercules, CA), and their purity was judged by SDS-PAGE. His6-fusion proteins were purified according to Qiagen (Valencia, CA).
###end p 14
###begin title 15
###xml 37 41 37 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTS1</italic>
Analysis of expression of endogenous CTS1 gene
###end title 15
###begin p 16
###xml 97 101 97 101 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTS1</italic>
###xml 106 110 106 110 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CMD1</italic>
###xml 143 145 143 145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd310c27">27</xref>
###xml 0 5 <span type="species:ncbi:4932">Yeast</span>
Yeast cells were grown on YPD media and RNA was isolated for S1 nuclease protection assays using CTS1 and CMD1 probes as described previously (27).
###end p 16
###begin title 17
GST pull-down assay
###end title 17
###begin p 18
###xml 81 82 77 78 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 98 99 94 95 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 164 165 160 161 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
Glutathione Sepharose beads (40 microl) were washed sequentially with 10 vol of H2O, 3.0 M NaCl, H2O, and binding buffer (40 mM HEPES, pH 7.5, 100 mM KCl, 5 mM MgCl2, 0.2 mM EDTA, 1 mM DTT, 0.5 mM PMSF, 0.5% NP-40, 0.25% milk). The beads were suspended in 0.4 ml of binding buffer, the purified GST fusion proteins were added and incubated at 4degreesC for 2 h. The beads were then washed twice with 10 vol of binding buffer and resuspended in 0.3 ml of binding buffer before the second protein was added. The mixture was incubated at 4degreesC for 1-3 h. The beads were washed twice with 10 vol of binding buffer, and then once with the binding buffer without milk. Forty-five microliters SDS-PAGE loading buffer was added and the mixture was boiled for 5 min. After centrifugation at 10 000 r.p.m. for 5 min, 15 microl of the supernatant was subjected to SDS-PAGE and assayed by either western blot or autoradiography. The amount of precipitated GST fusion protein, estimated by either western blot or Coomassie brilliant blue staining, was used for normalization as indicated in the figure legends.
###end p 18
###begin title 19
###xml 0 8 0 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In vitro</italic>
In vitro transcription assay
###end title 19
###begin p 20
###xml 90 96 90 96 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al.</italic>
###xml 98 100 98 100 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd310c12">12</xref>
###xml 235 239 235 239 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYC1</italic>
###xml 257 260 257 260 <sub xmlns:xlink="http://www.w3.org/1999/xlink">GAL</sub>
###xml 271 273 271 273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd310c28">28</xref>
TFIIB-depleted whole-cell extracts were prepared from strain FP133 as described by Bangur et al. (12). The plasmid pJJ470 used in this experiment is a gift from Dr J. Jaehning. It contains a 278 bp G-less cassette under the control of CYC1 TATA box with UASGAL upstream (28).
###end p 20
###begin title 21
Artificial recruitment assay
###end title 21
###begin p 22
###xml 71 77 71 77 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al.</italic>
###xml 79 81 79 81 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd310c26">26</xref>
###xml 268 270 268 270 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd310c26">26</xref>
Artificial recruitment assay was conducted according to Gonzalez-Couto et al. (26). Basically, our TFIIB mutant genes were cloned into a Myc-TFIIB vector. The encoded fusion proteins were then assayed for their abilities upon artificially recruited to a promoter (see 26 and text for further details).
###end p 22
###begin title 23
Gel shift assay of DB complex
###end title 23
###begin p 24
###xml 110 112 110 112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd310c29">29</xref>
###xml 200 201 200 201 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
The TATA-containing DNA probe was a 42-bp fragment that contains the adenoviral major late promoter TATA box (29). The reaction buffer contains 20 mM HEPES (pH 7.5), 50 mM KCl, 10 mM KOAc, 7.5 mM MgCl2, 2 mM DTT, 200 microg/ml BSA. The reaction mixture (20 microl) was incubated at room temperature for 30 min and loaded onto a 5% native polyacrylamide gel (29:1) immediately. The gel was run at room temperature in 1x TBE buffer at 150 V. The gel was then dried and subjected to autoradiography.
###end p 24
###begin title 25
RESULTS
###end title 25
###begin title 26
###xml 76 83 76 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
The TFIIB mutant YR1m4 is defective in supporting activated gene expression in vivo
###end title 26
###begin p 27
###xml 66 73 66 73 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 258 262 258 262 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTS1</italic>
###xml 326 339 326 339 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Saccharomyces</italic>
###xml 341 343 341 343 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd310c30">30</xref>
###xml 400 404 400 404 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTS1</italic>
###xml 549 550 549 550 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkd310f1">1</xref>
###xml 597 601 597 601 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTS1</italic>
###xml 700 701 700 701 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkd310f1">1</xref>
###xml 755 759 755 759 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACE2</italic>
###xml 853 855 853 855 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd310c30">30</xref>
###xml 905 909 905 909 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTS1</italic>
###xml 999 1000 999 1000 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkd310f1">1</xref>
###xml 1044 1048 1044 1048 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTS1</italic>
###xml 41 46 <span type="species:ncbi:4932">yeast</span>
###xml 529 534 <span type="species:ncbi:4932">yeast</span>
During the course of the analysis of our yeast TFIIB mutant YR1m4 in vivo, we observed that cells containing YR1m4 exhibited an aggregated phenotype (data not shown), suggesting a defect in cell separation. This phenotype resembles that of cells lacking the CTS1 gene, which encodes an endochitinase that hydrolyzes chitin in Saccharomyces (30). To determine whether the expression of the endogenous CTS1 gene is affected in YR1m4 cells, we carried out an S1 nuclease protection assay using mRNA isolated from different isogenic yeast strains (Fig. 1). Our results demonstrate that the endogenous CTS1 gene was expressed at a lower level in YR1m4 cells when compared to that in wild-type cells (Fig. 1A, lane 1 versus 2). Northern analysis indicates that ACE2 mRNA level in YR1m4 cells was unaffected (data not shown). Consistent with previous studies (30), our S1 assay results also demonstrate that the CTS1 expression is activated by ACE2 and independent of the homologous activator SWI5. Figure 1B is a summary of our S1 assay results with CTS1 expression levels normalized to an internal control.
###end p 27
###begin p 28
###xml 35 44 35 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYC1-lacZ</italic>
###xml 84 88 84 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTS1</italic>
###xml 119 122 119 122 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UAS</italic>
###xml 125 127 125 127 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd310c31">31</xref>
###xml 183 184 180 181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkd310f2">2</xref>
###xml 334 335 331 332 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkd310f2">2</xref>
###xml 611 612 608 609 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkd310f2">2</xref>
###xml 671 672 668 669 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkd310f2">2</xref>
###xml 821 824 818 821 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UAS</italic>
###xml 880 882 877 879 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd310c25">25</xref>
###xml 976 983 973 980 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
We also analyzed the activity of a CYC1-lacZ reporter gene under the control of the CTS1 upstream activation sequence (UAS) (31). Our beta-galactosidase assay results shown in Figure 2A (columns 1 and 2) demonstrate that ACE2 increased the transcription activity by 64.3-fold in wild-type cells but only 2.7-fold in YR1m4 cells (Fig. 2A, columns 3 and 4). In a similar reporter gene assay, transcription activation by an activator containing the transcription activation domain (TAD) of VP16 was also shown to be decreased. LexA-VP16 fusion protein activated transcription by 21.8-fold in wild-type cells (Fig. 2B, columns 1 and 2) but only 2.3-fold in YR1m4 cells (Fig. 2B, columns 3 and 4). In addition, our previous studies have demonstrated that several other artificial reporter genes under the control of different UASs were also affected to various extents in YR1m4 cells (25). Together, these results show that YR1m4 has a defect in supporting activated transcription in vivo.
###end p 28
###begin title 29
Interaction between YR1m4 and activators
###end title 29
###begin p 30
###xml 151 159 151 159 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 161 163 161 163 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd310c13">13</xref>
###xml 164 166 164 166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd310c14">14</xref>
###xml 502 510 502 510 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 573 574 573 574 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkd310f3">3</xref>
###xml 666 667 666 667 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkd310f3">3</xref>
###xml 925 932 925 932 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 955 957 955 957 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd310c25">25</xref>
###xml 1039 1040 1039 1040 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkd310f3">3</xref>
###xml 1140 1142 1140 1142 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd310c32">32</xref>
###xml 1183 1187 1183 1187 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADH2</italic>
TFIIB has been proposed to be a direct target for many transcriptional activators, primarily by virtue of protein-protein interaction assays conducted in vitro (13,14). To determine whether the interaction between TFIIB and the activators ACE2 and VP16 is affected by YR1m4 mutations, we carried out GST pull-down assays. In these assays, bacterially expressed and immobilized GST fusion proteins, containing either wild-type TFIIB or YR1m4, were used to precipitate activator proteins generated in an in vitro transcription/translation system. Our results shown in Figure 3 demonstrate that ACE2 and GAL4-VP16 can interact with both wild-type TFIIB and YR1m4 (Fig. 3A and B), suggesting that the residues mutated in YR1m4 do not directly interfere with the interaction between TFIIB and these activators. Another activator, native GAL4 with its own TADs, whose activation was only slightly affected in a reporter gene assay in vivo (<1.5-fold decrease) (25), can also interact with both wild-type TFIIB and YR1m4 in a similar assay (Fig. 3C). Among the tested activators that showed a decreased activity in YR1m4 cells, only TAD1 of ADR1 (32), which activates the expression of the ADH2 gene, exhibited a defect in interacting with YR1m4 (C.Denis, personal communication). Together, these experiments suggest that the inability of YR1m4 to interact with activators cannot be the only molecular defect accounting for its inability to support transcription efficiently.
###end p 30
###begin title 31
###xml 69 77 69 77 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 82 89 82 89 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
YR1m4 is defective in supporting activator-independent transcription in vitro and in vivo
###end title 31
###begin p 32
###xml 91 99 91 99 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 179 181 179 181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd310c12">12</xref>
###xml 353 354 353 354 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkd310f4">4</xref>
###xml 389 391 389 391 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd310c12">12</xref>
###xml 621 623 621 623 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd310c28">28</xref>
###xml 118 123 <span type="species:ncbi:4932">yeast</span>
To search for molecular defects associated with YR1m4, we carried out transcription assays in vitro. A TFIIB-depleted yeast whole cell extract was prepared from the strain FP133 (12) and supplemented with recombinant TFIIB, either wild-type or YR1m4. The extract itself does not support transcription due to the lack of sufficient amount of TFIIB (Fig. 4, lane 2). As previously reported (12), wild-type TFIIB can restore transcription efficiently (lane 3), which can be further increased by addition of GAL4-VP16 (lane 4); our assay was carried out using high template DNA concentrations, which, as previously reported (28), reduce the effect of activation. When YR1m4 was used in the same assay, it exhibited a severe defect in supporting both non-activated (lane 5) and activated transcription (lane 6).
###end p 32
###begin p 33
###xml 46 48 46 48 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd310c26">26</xref>
###xml 146 153 146 153 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 380 384 380 384 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lacZ</italic>
###xml 668 672 668 672 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lacZ</italic>
###xml 679 680 679 680 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkd310f5">5</xref>
###xml 1073 1075 1073 1075 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd310c26">26</xref>
###xml 1106 1107 1106 1107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkd310f5">5</xref>
###xml 1307 1311 1307 1311 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTS1</italic>
###xml 1389 1390 1389 1390 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkd310f1">1</xref>
###xml 1511 1519 1511 1519 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 1524 1531 1524 1531 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 1618 1625 1618 1625 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 1661 1662 1661 1662 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkd310f1">1</xref>
###xml 1708 1709 1708 1709 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkd310f5">5</xref>
###xml 1787 1788 1787 1788 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkd310f2">2</xref>
###xml 1823 1825 1823 1825 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd310c24">24</xref>
###xml 219 224 <span type="species:ncbi:4932">yeast</span>
###xml 487 492 <span type="species:ncbi:4932">yeast</span>
We also used an artificial recruitment assay (26) to further characterize the behavior of YR1m4 in supporting activator-independent transcription in vivo. In this experiment, a fusion protein, Max-RFX, was expressed in yeast cells. This protein contains the leucine zipper of Max fused to a DNA-binding protein RFX, which can recognize a RFX binding site (X) placed upstream of a lacZ reporter gene. The leucine zipper of c-Myc was attached to TFIIB at the C-terminus. When expressed in yeast cells, TFIIB-Myc fusion protein is recruited by Max-RFX through the hetero-dimerization interaction between Myc and Max, leading to the expression of the nearby reporter gene lacZ (Fig. 5A). Since no conventional DNA-binding activator is involved in this artificial recruitment assay, it measures the activator-independent function of TFIIB, reflecting its intrinsic properties (M.Strubin, personal communication). In this experiment, a non-functional TFIIB mutant, C48S, was used as a negative control, which showed only background activity in this assay as previously reported (26). Our results shown in Figure 5B demonstrate that YR1m4 has only 19% activity compared with that of wild-type TFIIB. It is interesting to note that, in the absence of both activators SWI5 and ACE2, the expression of the endogenous CTS1 gene in YR1m4 cells is decreased compared with that in wild-type cells (Fig. 1A, lanes 7 and 8). Together, our experiments suggest that YR1m4 is defective in activator-independent transcription both in vitro and in vivo. Interestingly, the defect of YR1m4 in supporting activator-independent transcription in vivo is more severe on endogenous (Fig. 1A, compare lanes 7 and 8) or integrated (Fig. 5) reporter genes than on reporter genes carried on replication plasmids (Fig. 2A and B, compare columns 1 and 3) (24), possibly reflecting differences in promoter accessibility.
###end p 33
###begin p 34
###xml 203 205 203 205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd310c24">24</xref>
###xml 206 208 206 208 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd310c25">25</xref>
We further tested in the artificial recruitment assay several other TFIIB mutants that have amino acid alterations in the same region mutated in YR1m4 but exhibit varying ability to support cell growth (24,25). Our experiments revealed a good correlation between their activity in this artificial recruitment assay and their ability to support cell growth. These findings further support the idea that the physiological phenotype associated with our TFIIB mutants results from their defects in supporting transcription.
###end p 34
###begin title 35
Interaction between TFIIB and other GTFs
###end title 35
###begin p 36
###xml 72 73 72 73 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd310c5">5</xref>
###xml 87 88 87 88 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd310c6">6</xref>
###xml 89 91 89 91 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd310c33">33</xref>
###xml 416 417 416 417 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkd310f6">6</xref>
###xml 467 475 467 475 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 487 489 487 489 <sup xmlns:xlink="http://www.w3.org/1999/xlink">35</sup>
###xml 563 564 563 564 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkd310f6">6</xref>
###xml 138 143 <span type="species:ncbi:4932">yeast</span>
Since TFIIB is able to interact with several other GTFs, including TBP (5) and RNAPII (6,33), it is possible that YR1m4 and other related yeast TFIIB mutants fail to support activator-independent transcription because they are defective in interacting with these factors. To test this idea directly, the interaction between TFIIB and both TBP and RNAPII was analyzed in GST pull-down experiments. As shown in Figure 6A, all the tested TFIIB mutants can interact with in vitro translated 35S-labeled TBP. These mutants can also interact with RNAPII normally (Fig. 6B and C).
###end p 36
###begin p 37
###xml 194 195 194 195 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkd310f7">7</xref>
###xml 626 628 626 628 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd310c21">21</xref>
We also performed a gel shift experiment to detect the formation of a DNA-TBP-TFIIB (DB) complex. This analysis allows the detection of TFIIB-TBP interaction on DNA. The results shown in Figure 7 demonstrate that the ability of YR1m4 to form the DB complex is not impaired. In fact, such complex formation is enhanced slightly (2-3-fold) for YR1m4; we currently do not fully understand the molecular basis for this observation, but it might be related to either the conformation properties of YR1m4 (see below) or subtle effects on the interaction with TBP-DNA complex although the mutated amino acids do not face TBP or DNA (21).
###end p 37
###begin p 38
###xml 159 161 159 161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd310c34">34</xref>
###xml 504 509 <span type="species:ncbi:4932">yeast</span>
In addition to TBP and RNAPII, we also tested the interaction between TFIIB and several other GTFs, including TFIIF, and two subunits of TFIIH, Tfb2 and Tfb3 (34). The Tfb2 subunit of TFIIH cannot interact with either wild-type or mutant TFIIB. TFIIF and Tfb3 are able to interact with TFIIB, but no difference was observed between wild-type TFIIB and YR1m4 (data not shown). The fact that the interaction between TFIIB and the tested GTFs is not affected by these mutations suggests that this region of yeast TFIIB is not directly involved in interacting with these factors individually. However, we cannot exclude the possibility that YR1m4 fails to directly interact with other GTFs not included in our tests.
###end p 38
###begin title 39
###xml 40 45 <span type="species:ncbi:4932">yeast</span>
Decreased intramolecular interaction in yeast TFIIB mutants
###end title 39
###begin p 40
###xml 110 112 110 112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd310c22">22</xref>
###xml 204 206 204 206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd310c15">15</xref>
###xml 219 225 219 225 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al.</italic>
###xml 227 229 227 229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd310c35">35</xref>
###xml 371 377 371 377 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E.coli</italic>
###xml 426 434 426 434 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 447 449 447 449 <sup xmlns:xlink="http://www.w3.org/1999/xlink">35</sup>
###xml 516 517 516 517 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkd310f8">8</xref>
###xml 761 762 761 762 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkd310f8">8</xref>
###xml 97 102 <span type="species:ncbi:9606">human</span>
###xml 161 166 <span type="species:ncbi:4932">yeast</span>
###xml 371 377 <span type="species:ncbi:110766|species:ncbi:562">E.coli</span>
An intramolecular interaction between the N-terminal domain and core domain has been observed in human TFIIB (22). Such an interaction has also been observed in yeast TFIIB as reported by Wu and Hampsey (15) and Bangur et al. (35). To determine whether the mutations in YR1m4 alter the intramolecular interaction, TFIIB core domain (amino acids 128-345) was expressed in E.coli as a GST fusion protein and used to precipitate in vitro synthesized 35S-labeled N-terminal domain (amino acids 1-135). Our results (Fig. 8A) show that, unlike wild-type TFIIB (lane 3), YR1m4 exhibits a weakened intramolecular interaction (lane 4). A titration experiment further confirmed that the intramolecular interaction is weakened in YR1m4 compared with wild-type TFIIB (Fig. 8B and C).
###end p 40
###begin p 41
###xml 242 244 242 244 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd310c24">24</xref>
###xml 245 247 245 247 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd310c25">25</xref>
###xml 507 514 507 514 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 589 590 589 590 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkd310f8">8</xref>
###xml 642 644 642 644 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd310c24">24</xref>
###xml 645 647 645 647 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd310c25">25</xref>
To determine whether the intramolecular interaction defect associated with YR1m4 is biologically relevant, we further analyzed the intramolecular interaction properties of several other related TFIIB mutants with varying phenotypic severity (24,25). Our experiments showed that all the related TFIIB mutants that were tested exhibited a weakened intramolecular interaction compared with wild-type TFIIB. More importantly, the intramolecular interaction properties of these mutants correlate well with their in vivo transcription activity detected in the artificial recruitment assay (Fig. 8D) as well as their ability to support cell growth (24,25). These results further illustrate the biological importance of intramolecular interaction of TFIIB.
###end p 41
###begin p 42
###xml 183 191 183 191 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 235 256 235 256 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Staphylococcus aureus</italic>
###xml 430 432 430 432 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd310c35">35</xref>
###xml 235 256 <span type="species:ncbi:1280">Staphylococcus aureus</span>
We performed a partial proteolysis assay to determine whether protease sensitivity is altered in YR1m4. Either the recombinant TFIIB protein with HA attached to the C-terminus or the in vitro synthesized TFIIB protein was subjected to Staphylococcus aureus V8 protease digestion. Under our experimental conditions, no significant difference was observed between wild-type TFIIB and YR1m4 (data not shown). As reported previously (35), the major V8 protease cleavage site is located in a hinge region between the N-terminal zinc ribbon domain and the core domain. It is possible that, in the absence of all the other factors that interact with TFIIB in the PIC, the altered intramolecular interaction of YR1m4 affects its conformation without generating a new protease sensitivity profile.
###end p 42
###begin title 43
DISCUSSION
###end title 43
###begin p 44
###xml 188 195 188 195 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 197 199 197 199 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd310c24">24</xref>
###xml 200 202 200 202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd310c25">25</xref>
###xml 512 520 512 520 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 653 660 653 660 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 948 955 948 955 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 962 963 962 963 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkd310f8">8</xref>
###xml 1013 1015 1013 1015 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd310c24">24</xref>
###xml 1016 1018 1016 1018 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd310c25">25</xref>
###xml 111 116 <span type="species:ncbi:4932">yeast</span>
The experiments described in this report were designed to further analyze the molecular properties of a mutant yeast TFIIB, YR1m4, which is defective in supporting activated transcription in vivo (24,25 and this report). Our biochemical studies show that YR1m4 is not defective in interacting directly with several affected activators. Furthermore, despite its ability to interact with several GTFs tested individually, this mutant TFIIB is severely compromised in supporting activator-independent transcription in vitro. In addition, we show that in an artificial recruitment assay, YR1m4 is defective in supporting activator-independent transcription in vivo. The intramolecular interaction between the N-terminal domain and core domain of this mutant is reduced in comparison with wild-type TFIIB. Our experiments reveal a strong correlation between the intramolecular interaction property and the activator-independent transcriptional activity in vivo (Fig. 8D) as well as the ability to support cell growth (24,25). Our results suggest that this intramolecular interaction of TFIIB plays an important role in proper transcription control in cells.
###end p 44
###begin p 45
###xml 113 114 113 114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd310c9">9</xref>
###xml 115 117 115 117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd310c12">12</xref>
###xml 118 120 118 120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd310c24">24</xref>
###xml 121 123 121 123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd310c36">36</xref>
###xml 148 150 148 150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd310c25">25</xref>
###xml 365 367 365 367 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd310c15">15</xref>
###xml 441 449 441 449 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 451 453 451 453 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd310c12">12</xref>
###xml 454 456 454 456 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd310c36">36</xref>
###xml 611 619 611 619 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 621 623 621 623 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd310c14">14</xref>
###xml 759 761 759 761 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd310c13">13</xref>
###xml 762 764 762 764 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd310c14">14</xref>
###xml 12 17 <span type="species:ncbi:4932">yeast</span>
Most of the yeast TFIIB mutants reported so far by our and other laboratories cause slow cell growth phenotypes (9,12,24,36). Our previous studies (25), as well as the current analysis, suggest that the slow growth phenotype of YR1m4 cells is due to a decreased expression of specific genes. While some TFIIB mutants were shown to have activation-specific defects (15), others were reported to be defective in supporting basal transcription in vitro (12,36). It has been shown that several mutant TFIIB molecules that are defective in interacting with certain activators fail to support activated transcription in vitro (14). Thus, it has been proposed that the direct recruitment of TFIIB by these activators can lead to an increased level of transcription (13,14). For YR1m4, we observed that most activators, except TAD1 of ADR1 (C.Denis, personal communication), could directly interact with the mutant TFIIB protein. These results suggest that the transcription defect associated with YR1m4 may result from a generally defective TFIIB and, in fewer cases, an impaired direct interaction between activators and YR1m4. Our finding that YR1m4 exhibits a weakened intramolecular interaction and is compromised in supporting activator-independent transcription further illustrates a general defect of this mutant protein.
###end p 45
###begin p 46
###xml 138 146 138 146 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 148 150 148 150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd310c22">22</xref>
###xml 151 153 151 153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd310c23">23</xref>
###xml 318 320 318 320 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd310c22">22</xref>
###xml 505 507 505 507 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd310c23">23</xref>
###xml 796 798 796 798 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd310c19">19</xref>
###xml 38 43 <span type="species:ncbi:9606">human</span>
###xml 305 310 <span type="species:ncbi:9606">human</span>
###xml 345 350 <span type="species:ncbi:9606">human</span>
###xml 613 618 <span type="species:ncbi:9606">human</span>
Biochemical and structural studies of human TFIIB suggest that conformational changes of TFIIB may contribute to transcription regulation in vitro (22,23). It was reported that the activation domain of VP16 could disrupt the intramolecular interaction between the N-terminal domain and the core domain of human TFIIB (22). Recent NMR studies of human cTFIIB suggest that VP16 and the N-terminal domain of TFIIB may compete with each other by interacting with the same or an overlapping surface on cTFIIB (23). Although the structure of full-length TFIIB protein is currently unavailable, NMR studies suggest that human TFIIB may adopt multiple conformations, resulting from both intramolecular interaction and the interaction with other factors, including GTFs and activators, as well as RNAPII (19). These studies suggest that TFIIB may undergo conformational changes in transcription.
###end p 46
###begin p 47
###xml 110 112 110 112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd310c15">15</xref>
###xml 113 115 113 115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd310c35">35</xref>
###xml 459 461 459 461 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd310c15">15</xref>
###xml 663 670 663 670 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 675 683 675 683 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 765 771 765 771 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al.</italic>
###xml 785 787 785 787 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd310c35">35</xref>
###xml 1026 1034 1026 1034 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 1043 1050 1043 1050 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 1052 1054 1052 1054 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd310c12">12</xref>
###xml 34 39 <span type="species:ncbi:4932">yeast</span>
Recent studies have described two yeast TFIIB mutants that affect the conformation properties of the protein (15,35). While both of those mutants contain amino acid alterations at the N-terminus (S53P and R64E), YR1m4 contains mutations in the core domain. In addition, YR1m4 exhibits biochemical and physiological properties that are different from those of the two reported mutants. In particular, while the S53P mutant protein described by Wu and Hampsey (15) shows a major conformational defect only in the presence of the activator protein PHO4, YR1m4 has an intramolecular interaction defect affecting both activated and activator-independent transcription in vivo and in vitro. While intramolecular interaction in the R64E mutant protein described by Bangur et al. is enhanced (35), this interaction is weakened in YR1m4. Interestingly, despite their opposite effects on intramolecular interaction, both R64E and YR1m4 are defective in supporting transcription, although transcription defect for R64E was detected only in vitro but not in vivo (12). Taken together, these studies suggest that efficient transcription and activation require a well-balanced intramolecular interaction of TFIIB, an interaction that may facilitate dynamic conformational changes of the protein.
###end p 47
###begin p 48
###xml 699 701 699 701 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd310c37">37</xref>
###xml 39 44 <span type="species:ncbi:4932">yeast</span>
We propose that, during PIC formation, yeast TFIIB is in a conformation that is stabilized by its intramolecular interaction. Upon PIC assembly, interactions with other proteins including activators may compete with and eventually break the intramolecular interaction of TFIIB, thus facilitating a subsequent step(s) of transcription initiation. According to this model, the weakened intramolecular interaction of YR1m4 is disfavored for PIC formation, even though it can interact with other GTFs individually. Our model is supported by a recent observation that one of the currently analyzed TFIIB mutants with a mutation in the species-specific region, C149R (YmC), has a defect in PIC formation (37). Regardless of the exact events taking place during transcription initiation and activation, our study underscores the importance of intramolecular interaction of TFIIB in controlling transcription in cells.
###end p 48
###begin title 49
Figures and Tables
###end title 49
###begin p 50
###xml 30 34 30 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTS1</italic>
###xml 70 71 70 71 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 209 213 209 213 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACE2</italic>
###xml 218 222 218 222 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SWI5</italic>
###xml 224 228 224 228 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CMD1</italic>
###xml 268 269 268 269 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 280 284 280 284 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTS1</italic>
###xml 375 379 375 379 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CMD1</italic>
###xml 136 141 <span type="species:ncbi:4932">yeast</span>
 The expression of endogenous CTS1 gene is decreased in YR1m4 cells. (A) S1 nuclease protection analysis of mRNA isolated from isogenic yeast strains that contain either wild-type TFIIB or YR1m4 and differ at ACE2 and SWI5. CMD1 was used as an internal control (31). (B) Relative CTS1 mRNA levels. Activities shown were quantitated by ImageQuant v1.2 and normalized with the CMD1 level. The values are 100, 29, 89, 28, 6, 5, 3, 0.3 in columns 1-8, respectively.
###end p 50
###begin p 51
###xml 77 84 77 84 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 87 88 87 88 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 96 100 96 100 <sub xmlns:xlink="http://www.w3.org/1999/xlink">TATA</sub>
###xml 101 105 101 105 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lacZ</italic>
###xml 172 175 172 175 <sub xmlns:xlink="http://www.w3.org/1999/xlink">UAS</sub>
###xml 393 394 390 391 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 402 404 399 401 <sub xmlns:xlink="http://www.w3.org/1999/xlink">OP</sub>
###xml 405 409 402 406 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYC1</italic>
###xml 409 413 406 410 <sub xmlns:xlink="http://www.w3.org/1999/xlink">TATA</sub>
###xml 414 418 411 415 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lacZ</italic>
###xml 204 209 <span type="species:ncbi:4932">yeast</span>
 The TFIIB mutant YR1m4 is defective in supporting activated gene expression in vivo. (A) A CYC1TATA-lacZ reporter plasmid with (pM1820) (31) or without (pLG670Z) (31) CTS1UAS element was introduced into yeast strain 604 containing a plasmid expressing either wild-type TFIIB or YR1m4. The absolute activities are 1.58, 101.54, 1.0 and 2.68 U beta-galactosidase in columns 1-4, respectively. (B) A LexAOP-CYC1TATA-lacZ reporter plasmid was introduced into the same strain as in (A). Plasmids that express either LexA-VP16 or LexA were transformed into the cells and assayed for beta-galactosidase activity. The absolute beta-galactosidase units are 4.6, 100.5, 2.8 and 6.4 in columns 1-4, respectively. All assays were done using three independent transformants in duplicate. The SDs are <20% in all cases.
###end p 51
###begin p 52
###xml 277 285 269 277 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 316 318 308 310 <sup xmlns:xlink="http://www.w3.org/1999/xlink">35</sup>
 YR1m4 interacts with activators ACE2, GAL4-VP16 and GAL4. Aliquots of 5 microg of purified GST, GST-TFIIB or GST-YR1m4 were incubated with 40 microl of glutathione Sepharose beads as described in Materials and Methods. The activators ACE2, GAL4-VP16 and full-length GAL4 were in vitro transcribed and translated as 35S-labeled proteins and 5 microl of lysate were used in each reaction. The precipitated proteins were applied to SDS-PAGE; 0.1 microl of lysate was used as input shown in the figure.
###end p 52
###begin p 53
###xml 48 56 48 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 58 66 58 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In vitro</italic>
 YR1m4 is defective in supporting transcription in vitro. In vitro transcription assay was performed with a TFIIB-depleted whole cell extract (12). This extract is unable to support transcription without the addition of recombinant TFIIB protein (lane 2). An aliquot of 2 microl of extract (~80 microg of protein) was used in the reaction. G-less cassette plasmid pJJ470 (100 ng) (28) were used as template. Purified recombinant TFIIB protein (50 ng), either wild type or YR1m4, was supplemented as indicated. Activated transcription was assayed upon the addition of 10 ng of purified GAL4-VP16 fusion protein.
###end p 53
###begin p 54
###xml 0 7 0 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In vivo</italic>
###xml 70 71 70 71 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 165 171 165 171 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al.</italic>
###xml 251 252 251 252 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
In vivo assay of the activator-independent transcriptional activity. (A) A schematic diagram depicting the artificial recruitment assay. See text and Gonzalez-Couto et al. (26) for further details. X, RFX binding site; Tx, transcription; IIB, TFIIB. (B) Relative activator-independent transcriptional activities of TFIIB derivatives. The level of beta-galactosidase activity upon the recruitment of wild-type TFIIB was assigned the number of 100. C48S, a single point mutation that abolishes the interaction between TFIIB and RNAPII (26), was used as a negative control. VP16-RFX, which contains a conventional activation domain VP16 fused to RFX, was used as a positive control.
###end p 54
###begin p 55
###xml 40 48 40 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 51 52 51 52 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 95 97 95 97 <sup xmlns:xlink="http://www.w3.org/1999/xlink">35</sup>
###xml 139 147 139 147 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 257 258 257 258 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 634 635 634 635 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C</bold>
###xml 869 876 869 876 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 107 112 <span type="species:ncbi:4932">yeast</span>
###xml 305 310 <span type="species:ncbi:4932">yeast</span>
 YR1m4 can interact with TBP and RNAPII in vitro. (A) GST-TFIIB derivatives can pull down TBP. 35S-labeled yeast TBP was synthesized in an in vitro transcription and translation system. See Materials and Methods and legend to Figure 3 for further details. (B) TFIIB-RNAPII interaction. Partially purified yeast RNAPII, kindly provided by Dr M. Sayre, was used in the pull-down experiment. The immobilized proteins were assayed by western blot using antibodies against the largest subunit of RNAPII (8WG16 from BABCO) and the GST (B-14, Santa Cruz Biotechnology). Input represents one-twentieth of the RNAPII used in the experiments. (C) The relative amount of immobilized RNAPII normalized by the amount of precipitated GST fusion proteins. Although there are light differences in the relative amounts of precipitated RNAPII, such differences do not correlate with the in vivo activity of the tested TFIIB derivatives.
###end p 55
###begin p 56
###xml 89 91 89 91 <sup xmlns:xlink="http://www.w3.org/1999/xlink">32</sup>
###xml 172 177 <span type="species:ncbi:4932">yeast</span>
 DB complex formation with wild-type TFIIB and YR1m4. The reactions contained 50 fmol of 32P-labeled 42-bp DNA fragments containing the ADMLP-2 TATA box. 20 ng of purified yeast TBP was added except in lane 1.
###end p 56
###begin p 57
###xml 86 87 86 87 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 207 215 207 215 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 228 230 228 230 <sup xmlns:xlink="http://www.w3.org/1999/xlink">35</sup>
###xml 621 622 621 622 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 731 733 727 729 <sup xmlns:xlink="http://www.w3.org/1999/xlink">35</sup>
###xml 1001 1002 993 994 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C</bold>
###xml 1107 1108 1099 1100 <bold xmlns:xlink="http://www.w3.org/1999/xlink">D</bold>
###xml 1178 1185 1170 1177 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 114 119 <span type="species:ncbi:4932">yeast</span>
###xml 373 378 <span type="species:ncbi:9606">human</span>
###xml 495 500 <span type="species:ncbi:4932">yeast</span>
###xml 670 675 <span type="species:ncbi:4932">yeast</span>
###xml 1292 1297 <span type="species:ncbi:4932">yeast</span>
 The intramolecular interaction is altered in YR1m4 and other related TFIIB mutants. (A) The C-terminal domain of yeast TFIIB (amino acid residues 128-345) was expressed as a GST fusion protein to pull down in vitro synthesized 35S-labeled N-terminal domain (amino acid residues 1-135). The experimental procedures were the same as described in the legend of Figure 3. The human TFIIB core domain (amino acid residues 124-315) was also included in this experiment, which failed to interact with yeast TFIIB N-domain. ND, N-terminal domain. Input represents one-twentieth of the lysate used in the pull down experiments. (B) Purified GST (5 microg), C-terminal domain of yeast TFIIB or YR1m4 was incubated with different amounts of 35S-labeled N-terminal domain (2, 4 and 8 microl of lysate in lanes 2-4, 5-7 and 8-10, respectively). G, GST; W, wild-type TFIIB C-terminal domain GST fusion; Y, YR1m4 C-terminal domain GST fusion; I, input, which represents one-tenth of the lysate used in lanes 8-10. (C) The amount of precipitated GST fusion proteins was estimated by SDS-PAGE and Coomassie blue staining. (D) Correlation between the intramolecular interaction property (A) and in vivo transcription activity (Fig. 5B). The amount of N-terminal domain pulled down by the C-terminal domain of yeast TFIIB was assigned the number 100.
###end p 57
###begin title 58
###xml 67 71 67 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTS1</italic>
###xml 0 5 <span type="species:ncbi:4932">Yeast</span>
Yeast strains used in the analysis of expression of the endogenous CTS1 gene
###end title 58
###begin title 59
ACKNOWLEDGEMENTS
###end title 59
###begin p 60
We thank Drs M. Sayre, R. Young, R. Kornberg, J. Jaehning, M. Strubin and A. Ponticelli for providing us with valuable materials, and Drs M. Barton, I. Cartwright, C. Denis, M. Strubin and members of our laboratories for discussions and comments on the manuscript. This publication was made possible by NIH grants GM48624 to D.J.S. and GM56215 to J.M., as well as NIH grant P30 ES06096 to University of Cincinnati.
###end p 60
###begin title 61
REFERENCES
###end title 61

